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Improved outcomes due to changes 
in organization of care for patients 
with ovarian cancer in 
the Netherlands
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Objectives of this study were to evaluate the effect of changes in patterns of care, for example 
centralization and treatment sequence, on surgical outcome and survival in patients with epithelial 
ovarian cancer (EOC). 
Methods
Patients diagnosed with FIGO stage IIB-IV EOC (2004-2013) were selected from the Netherlands 
Cancer Registry. Primary outcomes were surgical outcome (extent of macroscopic residual tumor 
after surgery) and overall survival.  Changes in treatment sequence (primary cytoreductive surgery 
and adjuvant chemotherapy (PCS+ACT) or neo-adjuvant chemotherapy and interval cytoreductive 
surgery (NACT+ICS)), hospital type and annual hospital volume were also evaluated. 
Results
Patient and tumor characteristics of 7987 patients were retrieved. Most patients were diagnosed with 
stage III-IV EOC. The average annual case-load per hospital increased from 8 to 28. More patients 
received an optimal cytoreduction (tumor residue ≤ 1cm) in 2013 (87%) compared to 2004 (55%, 
p<0.001). Complete cytoreduction (no macroscopic residual tumor), registered since 2010, increased 
from 42% to 52% (2010 and 2013, respectively, p<0.001).  Optimal/complete cytoreduction was 
achieved in 85% in high volume (≥20 cytoreductive surgeries annually), 80% in medium (10-19 surger-
ies) and 71% in small hospitals (<10 surgeries, p<0.001). Within a selection of patients with advanced 
stage disease that underwent surgery the proportion of patients undergoing NACT+ICS increased 
from 28% (2004) to 71% (2013). Between 2004 and 2013 a 3% annual reduction in risk of death was 
observed (HR 0.97, p<0.001). 
Conclusion
Changes in pattern of care for patients with EOC in the Netherlands have led to improvement in 
surgical outcome and survival. 
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INTRODUCTION
Epithelial ovarian cancer is the leading cause of death in gynecological malignancies (1), and the 
seventh most common cancer in women worldwide (2). In 2013 there were over 1200 new cases 
and around 1000 deaths as a result of ovarian cancer in the Netherlands (3). Due to a lack of specific 
symptoms, the majority of patients presents with advanced stage disease, resulting in a poor progno-
sis. Current treatment of advanced stage ovarian cancer consists of a combination of platinum-based 
chemotherapy and cytoreductive surgery. 
In the past decade, changes in the organization of care for patients with ovarian cancer have been 
implemented in the Netherlands. Traditionally, patients were staged and treated in the hospital of 
diagnosis. Consequently, less than 20% of ovarian cancer patients were treated in specialized hospi-
tals between 1996 and 2003 (4). Over the past decade increasing evidence has shown that complete 
cytoreduction is strongly correlated with improved disease free and overall survival, and that the 
likelihood of achieving this is higher when cytoreductive surgery is performed by a specialized gyne-
cologic oncologist in a high-volume hospital (5–14). These insights emphasized the need for improved 
regional collaboration and a larger ovarian cancer case load for a smaller number of hospitals and 
practitioners (9–11). Centralization initiatives undertaken by the Dutch Society of Obstetrics and 
Gynecology resulted in a nationwide consensus in 2011. Additionally, national standards for general 
and specialized cancer care were compiled. An important criterion in these national standards is 
that surgical cytoreduction for ovarian cancer should only be performed by specialized gynecologic 
oncologists in institutions in which a minimum of 20 cytoreductive surgeries take place annually. 
Increasing awareness of the importance of achieving complete cytoreduction has led to alterations in 
the therapy regimen for patients with advanced ovarian cancer (5–8,13). Administration of neoadjuvant 
chemotherapy to reduce tumor load and increase the chance of achieving complete cytoreduction 
was introduced after the publication of the EORTC-NCIC trial in 2010 (15). Comparison of standard 
therapy (primary cytoreductive surgery followed by adjuvant chemotherapy (PCS+ACT)) with the alter-
native regimen (neoadjuvant chemotherapy followed by interval cytoreductive surgery (NACT+ICS)) 
demonstrated equal progression free and overall survival chances (15–22). Additionally, reduced 
per- and postoperative complications following NACT+ICS were demonstrated (16–22). In several 
other publications, not being randomized controlled trials, less favorable outcomes such as inferior 
overall survival and increased toxicity due to chemotherapy, were depicted (23–25). Despite these 
variations in outcome however, the proportion of ovarian cancer patients treated with NACT+ICS has 
increased in recent years(16,18,20,26). 
The aim of the current study was to evaluate whether the changes in pattern of care for ovarian 
cancer patients, which have taken place in the Netherlands in the past decade, have led to improved 





Population-based data were retrieved from the Netherlands Cancer Registry (NCR), which is main-
tained by the Netherlands Comprehensive Cancer Organization. The NCR contains data of all cancer 
patients in the Netherlands, and relies on notifications of newly diagnosed malignancies from the 
automated nationwide pathology archive. Trained medical registrars use standardized forms to collect 
patient information from medical records and the national registry of hospital discharge diagnoses. 
Information regarding vital status and date of death is obtained through Statistics Netherlands, an 
agency responsible for the official Dutch statistics. Regular consistency checks are performed to 
ensure the quality of data in the NCR. 
Patients
Data from all consecutive patients diagnosed with FIGO stage IIB – IV ovarian cancer between January 
1st 2004 and January 1st 2014 in the Netherlands were retrieved. In total, 452 patients were excluded 
from analysis. These patients underwent unilateral or bilateral salpingo-oophorectomy (BSO) or hys-
terectomy with BSO only, and were excluded from analysis as these could not be classified as having 
had an attempt to achieve maximal cytoreduction, and patients that underwent staging only. Patient-, 
tumor- and treatment characteristics of 7987 patients were retrieved. Surgery performed within 9 
months of the date of diagnosis was considered related to ovarian cancer.   
To avoid understaging of patients undergoing neoadjuvant chemotherapy, determination of the 
stage of disease was dependent on the sequence of received treatments. Stage of disease was deter-
mined using the pathological TNM stage for patients who underwent PCS+ACT. For patients receiving 
NACT+ICS, stage of disease was determined before initiation of primary therapy and was based on the 
clinical TNM stage. After careful consideration and consultation by an experienced pathologist it was 
decided to view serous and adenocarcinoma not otherwise specified (NOS) subtypes as one entity.
Hospitals
Hospitals were categorized into three groups: academic hospitals, specialized hospitals, and general 
hospitals. Academic hospitals are tertiary referral hospitals that deliver highly specialized care, and 
are related to a university. Specialized hospitals are teaching hospitals that are not related to a univer-
sity. General hospitals are non-teaching hospitals and are usually smaller than specialized hospitals. 
Hospital volume was defined as the average annual number of cytoreductive surgeries performed 
for ovarian cancer between 2004 and 2013. Annual volumes of 1-3 cytoreductive surgeries were 
considered to be incidents, and were not included in the volume-analysis. 
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Outcomes 
Primary outcomes were surgical outcome and overall survival.  During the study period several alter-
ations in definitions of cytoreductive outcome occurred within the NCR registration (table 1). The 
term complete cytoreduction was introduced in the NCR in 2009 and fully implemented by 2010. 
Comparison of complete cytoreductive outcomes is therefore only possible between 2010 and 2013. 
To allow comparison of outcomes within the whole study period (2004-2013), optimal and complete 
results of cytoreductive surgery were compiled into one variable. Treatment sequence (PCS+ACT or 
NACT+ICS), type of treatment hospital and annual number of cytoreductive surgeries per hospital 
were also evaluated. 
Table 1. Definitions utilized by NCR for result of cytoreductive surgery
Term Definition in 2004-2006 Definition in 2007-2009 Definition in 2010 onwards
Incomplete Residual tumor >2cm Residual tumor >1cm Residual tumor >1cm
Optimal Residual tumor ≤2cm Residual tumor ≤1cm Residual tumor ≤1cm
Complete - - No macroscopic residual tumor
Within the selection of patients fulfilling all in- and exclusion criteria, patients in whom ovarian cancer 
was detected by coincidence without an attempt to remove macroscopic tumor tissue, and patients 
who underwent surgery that was not further specified, were all categorized as having received incom-
plete cytoreduction.
Data analysis
Data analysis was performed using STATA data analysis and statistical software (StataCorp, College 
Station, TX). Comparison between unpaired groups was done using the Chi2 test. Overall survival was 
used as primary survival outcome measure, and estimated using Kaplan Meier analyses. To correct 
for possible confounders such as age, stage, type of tumor, grade and treatment sequence, multi-
variable survival analyses were performed using Cox regression. Year of diagnosis was entered into 
these analyses as a continuous variable. To avoid immortal time bias when comparing survival rates 
between the patients that received PCS and the patients that received NACT-ICS, conditional survival 
analysis was used. It was assumed that all patients underwent cytoreductive surgery and the first 3 
chemotherapy cycles within 6 months after diagnosis. Thus, survival analyses were performed with 




Data from 7987 patients were retrieved for this study. Clinicopathological characteristics are shown in 
table 2. Within the study-population, most patients were diagnosed with stage IIIC (60%) and serous 
type (86%) ovarian cancer. Primary cytoreductive surgery was the most frequently chosen therapeutic 
regimen. Overall, 73% of patients underwent surgery and 27% did not. The proportion of patients 
that did not undergo surgery increased from 21% in 2004 to 32% in 2013. Of the patients who did 
not receive surgery, 52% underwent chemotherapy, 5% had hormonal therapy or other palliative 
treatment, and in 43% further treatment was unknown or not indicated. In general, patients that 
did not receive surgery were older than those who did receive surgical treatment (75 years and 63 
years respectively, P<0.001, data not shown). Between 2004 and 2013, the average age of patients 
increased from 65 years (95%CI 64-65) to 68 years (95%CI 67-69). 
The number of hospitals performing cytoreductive surgery for ovarian cancer patients decreased 
from 90 hospitals in 2004 to 34 hospitals in 2013. As a consequence, the average annual caseload 
per hospital increased from 8 cases in 2004 to 28 cases in 2013. In total, 15 out of the 34 hospitals 
(44%) involved in cytoreductive surgery for ovarian cancer in 2013 met the minimal requirement of 
20 cytoreductive surgeries per hospital per year (data not shown). 
Surgical outcomes
Within the study period an increase in the amount of complete/optimal cytoreductions was achieved: 
55% in 2004 compared to 87% in 2013 (p<0.001 with test for trend, figure 1). Between 2010 and 
2013 an increase in the rate of complete cytoreduction was seen from 42% to 52% (p<0.001, data not 
shown). Patients in whom a complete cytoreduction was achieved had a favorable survival compared 
to those who underwent an optimal or incomplete cytoreduction (data not shown). 






































Changes in organization of ovarian cancer care
A correlation was found between hospital volume and the number of patients who underwent a com-
plete cytoreduction. Hospitals with an annual volume of ≥20 cytoreductive surgeries achieved better 
cytoreductive outcomes than hospitals with annual volumes of 10-19 and <10 surgeries. Complete/
optimal cytoreduction was achieved in 85%, 80% and 71% respectively (P<0.001, figure 2). Between 
2010 and 2013, complete cytoreduction was achieved in 57%, 45% and 44% in hospitals that per-
formed >20, 10-19 and <10 cytoreductive surgeries annually (p<0.001). Hospitals that performed 
≥30 cytoreductive surgeries annually attained more complete cytoreductions compared to those 
that performed 20-29 cytoreductive surgeries (59% and 50% respectively between 2010 and 2013 
(p=0.003, data not shown). 





















In hospitals that performed ≥20 cytoreductive surgeries annually, an optimal/complete cytoreduction 
was achieved in 69% of patients in 2004, compared to 89% in 2013. Likewise, in hospitals with an 
annual volume of <10 cytoreductive surgeries, optimal/complete cytoreduction was achieved in 43% 
of patients in 2004, compared to 83% in 2013. An unfavorable survival was found in patients that 
were treated in hospitals with an annual volume of < 10 cytoreductions, compared to hospitals with 
an annual volume of 10-19 or ≥20 cytoreductive surgeries (data not shown). 
Academic hospitals achieved better surgical outcomes than specialized and general hospitals. Com-
plete/optimal cytoreduction was achieved in 84%, 79% and 71% respectively (p<0.001 with chi2 test, 
figure 3). Between 2010 and 2013, complete cytoreduction was achieved in 53%, 48% and 42% 
respectively (p=0.002, data not shown). There were no differences in the number of patients with 
FIGO stage IIIC or IV between the three hospital types (p=0.227, data not shown). 
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In patients with advanced stage disease who received NACT+ICS a complete/optimal cytoreduc-
tion was reached in 81%, compared to 69% in patients who received PCS+ACT (p<0.001, figure 4). 
Between 2010 and 2013, 47% of patients with advanced stage disease that underwent NACT+ICS 
received a complete cytoreduction versus 43% of patients that underwent PCS+ACT (p=0.028). In 
patients receiving ICS after initial PCS+ACT surgical outcome was poor (data not shown). PCS+ACT 
followed by ICS is not part of standard therapy for patients with ovarian cancer in the Netherlands, as 
illustrated by the small number of patients involved (table 2). Patients who underwent PCS+ACT+ICS 
were generally younger and more frequently diagnosed with high stage serous ovarian cancer than 
those who underwent standard PCS+ACT therapy (data not shown).  

























PCS: primary cytoreductive surgery, ACT: adjuvant chemotherapy, NACT: neoadjuvant chemotherapy, ICS: interval 
cytoreductive surgery.
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Table 2. Clinicopathological characteristics of total patient population
  Total (n=7987)
  n %
FIGO Stage    
    IIB 306 4
    IIC 332 4
    IIIA 210 2
    IIIB 534 7
    IIIC 4769 60
    IV   1836 23
Type of tumor    
    Serous 6856 86
    Mucinous 281 4
    Endometrioid 432 5
    Clear cell 222 3
    Other 196 2
Grade    
    I 304 4
    II 889 11
    III 3004 38
    Anaplastic 38 0
    Undefined 3752 47
Treatment    
    Surgery 5870 73
        PCS +ACT 3004 51
        NACT+ICS 2635 45
        PCS+ACT+ICS 231 4
    No surgery 2117 27
Age at diagnosis (years)    
    Mean (range) 66 (20-97)  
FIGO: International Federation of Gynecology and Obstetrics; PCS: primary cytoreductive surgery; ACT: adjuvant 




Within the group of patients diagnosed with stage IIB-IV ovarian cancer, a small improvement in five 
year overall survival was demonstrated between patients diagnosed in 2004-2006 (24%) and 2010-
2013 (25%, HR 0.91, 95% CI 0.84-0.99, p=0.031).  One year overall survival increased from 82% (95% 
CI 0.78-0.85) in 2004 to 90% (95% CI 87-92, p<0.001) in 2013 (p<0.001). Additionally, a 2% annual 
reduction in risk of death was demonstrated between 2004 and 2013 (HR 0.983, 95% CI 0. 970-
0.995, p=0.007, univariable analysis).  Multivariable analysis, correcting for age, stage, type of tumor 
and grade, demonstrated a 3% annual reduction in risk of death (HR 0.974, 95% CI 0.962 – 0.987, 
p<0.001, Table 3). 
Table 3. Multivariate analysis of overall survival between 2004 and 2013 
HR 95% CI p-value
Year of diagnosis 0.974 0.962 0.987 <0.001
Age 1.020 1.017 1.023 <0.001
Stage
    IIB ref ref ref ref
    IIC 1.275 0.959 1.700 0.094
    IIIA 2.456 1.832 3.292 <0.001
    IIIB 2.325 1.819 2.971 <0.001
    IIIC 3.348 2.702 4.149 <0.001
    IV 4.503 3.611 5.616 <0.001
Grade
    I ref ref ref ref
    II 1.480 1.220 1.795 <0.001
    III 1.412 1.177 1.695 <0.001
    Anaplastic 1.883 1.096 3.233 0.022
    Unknown 1.414 1.175 1.701 <0.001
Type of tumor
    Serous ref ref ref ref
    Mucinous 2.083 1.770 2.451 <0.001
    Endometrioid 0.882 0.766 1.015 0.081
    Clearcell 1.392 1.162 1.667 <0.001
    Undefined 1.246 0.946 1.641 0.118
HR: hazard risk; CI: confidence interval.
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Treatment regimens
A total of 5870 patients underwent cytoreductive surgery for ovarian cancer in the Netherlands 
between 2004 and 2013. Within this timeframe, the proportion of patients receiving PCS+ACT 
decreased considerably, whereas the proportion of patients receiving NACT+ICS showed a steady 
increase (figure 5). Patients receiving NACT+ICS were more frequently diagnosed with advanced stage 
and serous disease compared to patients receiving PCS+ACT (p<0.001 in both cases, data not shown). 
Within the selection of patients with advanced stage disease (FIGO IIIC-IV) who underwent complete/
optimal cytoreduction, patients receiving PCS+ACT had a 5-year overall survival of 39% (95% CI 36-42) 
compared to 26% (95% CI 23-28) in those receiving NACT+ICS.





































PCS: primary cytoreductive surgery, ACT: adjuvant chemotherapy, NACT: neoadjuvant chemotherapy, ICS: interval 
cytoreductive surgery.
The treatment sequence of NACT followed by interval cytoreductive surgery was introduced earlier in 
academic hospitals compared to specialized and general hospitals. In 2004, 38% of patients treated in 
academic hospitals received NACT+ICS compared to 20% in specialized and 21% in general hospitals. 
By 2013 all hospital types routinely performed NACT+ICS (64%, 59% and 63% of patients treated in 




To our knowledge, this is the largest population-based study analyzing the changes in pattern of care 
for ovarian cancer patients within the past decade.  A unique feature of the current study is that within 
the study period all patients were treated with the standard first line platinum based chemotherapy. 
We observed an increase in the rate of complete/optimal cytoreduction and simultaneously a small 
decrease in annual risk of death. 
Improvement in surgical outcomes may be related to the organizational changes that have been 
implemented during recent years. Implementation of national standards has enforced regional collab-
oration and the presence of specialized gynecologic oncologists during cytoreductive surgeries. Both 
of these factors are associated with favorable surgical outcomes and survival (9–11,14). Furthermore, 
rapid implementation of new guidelines and the presence of specialized personnel and state of the 
art facilities in high volume and specialized hospitals contribute strongly to the high standards of 
care within these institutions. 
Our results demonstrate an association between the type and volume of treatment hospital and 
the outcome of cytoreductive surgery. Although surgical outcomes improved in both low and high 
volume hospitals between 2004 and 2013, hospitals that met the volume requirements (≥20 surgeries 
annually) attained better surgical outcomes than hospitals with lower annual volumes. 
Furthermore, academic hospitals and specialized hospitals reported better cytoreductive outcomes 
than general hospitals. In 2013, 44% of the hospitals that performed cytoreductive surgeries for ovarian 
cancer in the Netherlands met the annual volume requirements of ≥20 cytoreductive surgeries. Consid-
ering the association between high annual surgical volumes, centralization of care and improvement of 
surgical outcomes, stricter implementation of national standards is deemed essential.
An unfavorable survival was found in patients that were treated in hospitals with an annual volume 
of <10 cytoreductive surgeries, compared to hospitals with an annual volume of 10-19 or ≥20 cytore-
ductive surgeries. Analysis of volume effects on survival may require a longer follow up time than is 
currently available. Although centralization initiatives started in 2005, the official implementation of 
centralization of care in the Netherlands took place in 2013. 
A previous Dutch study demonstrated that patients undergoing surgery by high volume surgeons 
(the definition of high volume ranging between performing >10 and >12 cytoreductive surgeries for 
ovarian cancer annually) have lower operative mortality rates. Furthermore, an association was found 
between surgery performed by high volume surgeons and higher rates of adherence to treatment 
guidelines (27–30). Nevertheless, no volume requirements currently exist for individual gynecologic 
oncologists in the Netherlands (10,31). 
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Besides the changes in the organization of care, alterations in the therapeutic regimens themselves have 
contributed to the improvement seen in surgical outcomes. While the effect of cytoreductive outcome 
on survival is undisputed, the timing of cytoreductive surgery has been, and still is, subject of debate. 
Our nationwide study depicts the increased implementation of NACT+ICS in the Netherlands during 
recent years, a trend that was previously described by Van Altena et al (26). Though there are no official 
guidelines, patients deemed unsuitable candidates for primary surgery are selected for NACT+ICS to 
downstage the tumor, facilitate subsequent cytoreduction and reduce damage to surrounding tissue. 
Women receiving NACT+ICS are often older, have more comorbidity and generally have tumors of 
higher grade and stage(32). A complete/optimal cytoreduction was achieved in 81% of women with 
advanced stage disease who received NACT+ICS, compared to 69% of those who underwent PCS+ACT. 
Favorable surgical outcomes following NACT+ICS were previously reported in a randomized clinical 
trial by Vergote et al, in which residual tumor of ≤1cm was achieved in 81% with ICS and 42% with 
PCS (15). Similarly, a Cochrane review reported favorable cytoreductive outcome in the NACT+ICS 
group compared to the PCS+ACT group (RR 2.56; 95% CI 2.00-3.28)(21). 
In the current study 27% of patients did not undergo any cytoreductive surgery. This is consistent 
with similar data from the Dutch population between 1996 and 2004 (26). Furthermore, a recent 
analysis of 9491 stage III/IV ovarian cancer patients in the population-based Surveillance, Epidemi-
ology and End Results (SEER)-database from the United States, also showed that 27% of patients 
did not undergo surgery. (33).  It may be expected that the proportion of patients that is unable to 
undergo cytoreductive surgery will rise as the age of patients with ovarian cancer slowly increases. 
Within the current study, a minority (4%) of patients received ICS after initial PCS+ACT. It has pre-
viously been demonstrated that the addition of secondary cytoreductive surgery to postoperative 
platinum-based chemotherapy does not improve survival in patients with a residual tumor exceeding 
1 cm after having a maximal effort during primary cytoreductive surgery, supporting the fact that this 
regimen is not standard practice in the Netherlands (34). 
Within our retrospectively selected study population, patients who underwent PCS+ACT had favor-
able survival outcomes compared to patients who underwent NACT+ICS.  Patients were selected for 
NACT+ICS based on initial unfavorable prognostic characteristics such as advanced stage disease and 
severe comorbidity. The unfavorable long term survival seen in patients who underwent NACT+ICS 
is therefore most likely a reflection of the selection bias within this retrospective study. This bias may 
readily explain the fact that our findings greatly differ from the results of two large randomized con-
trolled trials (EORTC-NCIC and CHORUS) in which non inferiority of survival following NACT+ICS was 
demonstrated (15,22).  Importantly, the EORTC-NCIC trial has been criticized for the short median 
survival rates (29-30 months) and the disappointing surgical outcomes (optimal cytoreduction was 
achieved in only 42% of patients randomized to PCS+ACT) that were reported. 
34
Chapter 2
Of note, patients were categorized in the NACT+ICS group under the condition that ICS was per-
formed, implying that they must have survived the NACT. For patients categorized as PCS+ACT, no 
such conditions were in place. As this may have led to an immortal time bias, a landmark analysis 
was used as described above.  
A small but significant improvement in five-year overall survival was demonstrated between the peri-
ods 2004-2006 and 2010-2013, and one year overall survival increased from 82% to 90% between 
2004 and 2013. Furthermore, the decrease in annual risk of death, as demonstrated in the current 
study, remained significant when correcting for, stage, type of tumor and grade, suggesting that 
other factors than these played a role in this association. The increasing  proportion of complete 
cytoreductions attained within recent years is thought to be an important factor for the improved 
survival, but centralization may have played an important role as well(6–8,13). 
The fact that we observed an improvement in five-year survival is encouraging, as previous survival 
analyses failed to show improvement. A study by Van Altena et al on the influence of regional collab-
oration in treatment for ovarian cancer in the Netherlands did not show a significant improvement 
in five-year overall survival rates between 1996 (36%) and 2010 (39%) (9). Similarly, the CONCORD-2 
study estimated stable five-year net survival rates in the Netherlands between 1995-1999 (39%), 
2000-2004 (37%) and 2005-2009 (38%)(35).  The EUROCARE-5 study recently published survival data 
from ovarian cancer patients in individual European countries between 1999 and 2007. Within that 
period, five-year net survival of Dutch patients with ovarian cancer was 39.9 (95%CI 38.7-41.1)(36). 
Survival in the CONCORD-2-study and EUROCARE-5 study was adjusted for background mortality 
by age, sex, and calendar year. Importantly, survival rates in the current study are lower than those 
reported by Van Altena et al and in the CONCORD-2 and EUROCARE-5 studies due to inclusion of 
patients with early stage ovarian cancer in those studies. 
The importance of reaching an optimal or complete cytoreduction has become increasingly evi-
dent. Chang and colleagues demonstrated a 2.3-month increase in cohort median survival time for 
each 10% increase in patients that received a complete cytoreduction as compared to a 1.8-month 
improvement for each 10% increase  in patients that received an optimal cytoreduction(8). Addition-
ally, a recent analysis of GOG 182 showed a significant improvement in survival between optimal 
cytoreduction and complete cytoreduction (progression free survival of 15 versus 29 months, and 
overall survival of 41 and 77 months, respectively, P=0.01 for both)(13).  It is important to note that as 
a relatively short follow-up was available for patients diagnosed within the most recent years of our 
study, the effects of the changes implemented in recent years may not have been fully appreciated.
The retrospective nature of this study has some inevitable limitations. First of all, this study was 
based on data from the NCR, and thus relies on the data that are available in this registration. In 
this database no information was registered about the specific chemotherapy regimens that were 
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used. As national guidelines regarding chemotherapy for EOC patients did not change within the 
study period, we assume all patients were treated with the same standard first line platinum based 
chemotherapy. However, we cannot exclude that there may have been some minor variations in 
chemotherapy regimens. 
Our study also relies on the accuracy of the NCR. Patient registration in the NCR is performed by 
trained and dedicated registrars and the data are regularly checked to ensure optimal quality of 
the database. It is important to note that registrars depend on the integrity of information available 
in local medical records. Nonetheless, the NCR is currently the most reliable nationwide source of 
information on cancer patients in the Netherlands. 
Furthermore, the comparison of cytoreductive results is complicated by variation in definitions used 
worldwide.  During the study period changes also occurred within the definitions used for registra-
tion in the NCR (table 1). Complete cytoreduction was registered from 2010 onward. Compilation of 
complete and optimal cytoreductive outcomes enabled comparison throughout the study period, 
though changes within optimal cytoreduction that occurred within this timeframe were not taken 
into account. 
Finally, the nature of the study precludes the determination of the individual contribution of factors 
such as centralization and changes in therapy regimes on the improvement in survival. 
 
In conclusion, in this study, regarding 7987 patients diagnosed with ovarian cancer FIGO stage IIB 
and higher, changes in pattern of care for ovarian cancer patients between 2004 and 2013 were 
evaluated. A combination of centralization initiatives and changes in therapy regimens has led to 
improvements in surgical outcome and survival. Continuing centralization of oncological care and 
implementation of stricter guidelines may lead to further improvement of survival for patients with 
ovarian cancer in the Netherlands.  
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